Eligible patients (range, age 18–60 years) had AML with FLT3-ITD mutations, received allo-SCT, had an ECOG performance status below grade 2, were in a CRc state before and after SCT, and had hematopoietic recovery within 60 days of SCT (Table 3) [71]. This evidence concerns the gene FLT3 and acute myeloid leukemia.